Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Immunogenicty and Anti-Reservoir Activity of an Electroporation-Administered HIV DNA Vaccine Encoding GAG, POL and ENV Proteins With IL-12 Plasmid in HIV-Infected Adults on Antriretroviral Therapy.

NCT03606213 is registered in ClinicalTrials.gov with Steven Deeks as lead sponsor.

NCT NCT03606213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03606213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Immunogenicty and Anti-Reservoir Activity of an Electroporation-Administered HIV DNA Vaccine Encoding GAG, POL and ENV Proteins With IL-12 Plasmid in HIV-Infected Adults on Antriretroviral Therapy.
Lead sponsor
Steven Deeks
Phase
Phase 1/2
Overall status
Completed
Start date
August 1, 2018
Completion date
May 17, 2021
Enrollment
56 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection